The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
Abstract CINSARC, a multigene expression signature originally developed in sarcomas, was shown to have prognostic impact in various cancers. We tested the prognostic value for disease-free survival (DFS) of CINSARC in a series of 6035 early-stage invasive primary breast cancers. CINSARC had independ...
Guardado en:
Autores principales: | Anthony Goncalves, Pascal Finetti, Daniel Birnbaum, François Bertucci |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ecafbdc5cfd6482fbd26fa13182d387e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Andrea Gombos, et al.
Publicado: (2021) -
Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB
por: Arumugam Nagalingam, et al.
Publicado: (2021) -
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer
por: Amanda Bortolini Silveira, et al.
Publicado: (2021) -
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
por: Xi Jiao, et al.
Publicado: (2021) -
Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome
por: Juliana C. Wortman, et al.
Publicado: (2021)